Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment for Weight Loss

Side-by-Side Comparison

How the Mechanisms Differ

Retatrutide: Three Receptors, One Molecule

Retatrutide activates three receptor systems simultaneously:

• GLP-1 receptor — suppresses appetite through hypothalamic and brainstem signaling, slows gastric emptying
• GIP receptor — enhances insulin secretion and may improve fat metabolism
• Glucagon receptor — increases energy expenditure through thermogenesis and promotes hepatic fat oxidation

AOD-9604: Targeted Fat Metabolism

AOD-9604 is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone (amino acids 176-191). It was designed to isolate the fat-burning effects of growth hormone without the broader hormonal side effects.

AOD-9604 works through two mechanisms:

• Stimulates lipolysis — activates beta-3 adrenergic receptors in adipose tissue, promoting breakdown of stored fat
• Inhibits lipogenesis — blocks enzymes involved in new fat formation

Why This Matters

The fundamental difference: retatrutide changes how much you eat and how much energy your body burns. AOD-9604 only changes how your body processes existing fat stores — without affecting hunger or metabolic rate at a systemic level.

Weight Loss Data

Retatrutide Clinical Results

In the Phase 2 trial, over 90% of participants on the highest dose lost at least 10% of body weight, and approximately 75% lost at least 20%. These are the highest weight loss numbers ever recorded for any anti-obesity drug in clinical trials.

AOD-9604 Clinical Results

The first Phase 2b trial (n=300) showed modest weight loss of 2.8 kg at the 1 mg oral dose over 12 weeks, with the lowest dose performing best — an unusual inverse dose-response pattern that raised questions.

The Evidence Gap

To put the numbers in perspective:

• Retatrutide produced approximately 24-29 kg of weight loss in average participants over 48-68 weeks
• AOD-9604 produced, at best, 2.0 kg more than placebo over 12 weeks — and its larger trial showed no significant benefit at all

This is not a matter of degree. Retatrutide has Level 1 evidence (large randomized controlled trials published in the New England Journal of Medicine). AOD-9604 has a failed Phase 2b trial and abandoned development.

Safety Comparison

AOD-9604 has a favorable safety profile — a 2013 meta-analysis of six trials (n=900+) found it "indistinguishable from placebo" in terms of adverse events, with no effect on glucose metabolism, IGF-1, or immune response. It received FDA GRAS (Generally Recognized As Safe) status as a food additive for the oral form.

However, this safety advantage is largely because AOD-9604 has minimal biological activity at the doses tested. A drug that produces no meaningful weight loss compared to placebo is unlikely to produce significant side effects either.

Regulatory and Access Comparison

Can You Combine AOD-9604 With Retatrutide?

The risks of combining them include:

• No safety data exists for the combination
• AOD-9604's own efficacy data is weak
• Adding an unproven compound to a potent drug introduces unknown variables
• Retatrutide is not available outside of clinical trials, so anyone combining them is using gray market products

Frequently Asked Questions

Sources

• Jørgensen, J.O.L., et al. (2004). Phase 2b trial of oral AOD-9604 in obese subjects. Metabolic Pharmaceuticals press release, December 2004.
• Metabolic Pharmaceuticals. (2007). OPTIONS Study results. The Age, Feb 21, 2007.
• Stier, H., Vos, E., Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 3(1-2):7-15.
• Heffernan, M.A., et al. (2001). Effects of hGH and AOD9604 on lipid metabolism in obese mice. Endocrinology. PMID: 11713213.
• Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972.
• Eli Lilly. (2025). TRIUMPH-4 results. Press release.